ADX-71149

ADX-71149
Clinical data
ATC code	None;
Identifiers
	IUPAC name 1-Butyl-3-chloro-4-(4-phenylpiperidin-1-yl)-1,2-dihydropyridin-2-one;
CAS Number	1127498-03-6;
PubChem CID	25195461;
IUPHAR/BPS	8946;
ChemSpider	28424210;
UNII	612BYT76F3;
ChEMBL	ChEMBL3337527;
Chemical and physical data
Formula	C20H25ClN2O
Molar mass	344.88 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCN1C=CC(=C(C1=O)Cl)N2CCC(CC2)C3=CC=CC=C3;
	InChI InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3; Key:HYOGJHCDLQSAHX-UHFFFAOYSA-N;

Short description: Chemical compound

ADX-71149, also known as JNJ-40411813 and JNJ-mGluR2-PAM, is a selective positive allosteric modulator of the mGlu₂ receptor.^[1]^[2]^[3] It is being studied by Addex Therapeutics and Janssen Pharmaceuticals for the treatment of schizophrenia.^[4] It was also researched by these companies for the treatment of anxious depression (major depressive disorder with anxiety symptoms),^[5] but although some efficacy was observed in clinical trials, it was not enough to warrant further development for this indication.^[6] (As of 2015), ADX-71149 is in phase II clinical trials for schizophrenia.^[4]

References

↑ "Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor". Journal of Medicinal Chemistry 57 (15): 6495–512. August 2014. doi:10.1021/jm500496m. PMID 25032784.
↑ "Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor". Pharmacology Research & Perspectives 3 (1): e00096. February 2015. doi:10.1002/prp2.96. PMID 25692015.
↑ "Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813". Pharmacology Research & Perspectives 3 (2): e00097. March 2015. doi:10.1002/prp2.97. PMID 25692027.
↑ ^4.0 ^4.1 "Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics". Current Opinion in Pharmacology 20: 40–5. February 2015. doi:10.1016/j.coph.2014.11.003. PMID 25462291.
↑ "Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?". Journal of Psychopharmacology 29 (2): 230–8. February 2015. doi:10.1177/0269881114565806. PMID 25586401.
↑ Addex Therapeutics (7 February 2014). "Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms". http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder/.

External links

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/ADX-71149. Read more

[CidTresadern2014-1] "Discovery of 1-butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): a novel positive allosteric modulator of the metabotropic glutamate 2 receptor". Journal of Medicinal Chemistry 57 (15): 6495–512. August 2014. doi:10.1021/jm500496m. PMID 25032784.

[LavreysenAhnaou2015-2] "Pharmacological and pharmacokinetic properties of JNJ-40411813, a positive allosteric modulator of the mGlu2 receptor". Pharmacology Research & Perspectives 3 (1): e00096. February 2015. doi:10.1002/prp2.96. PMID 25692015.

[LavreysenLanglois2015-3] "Preclinical evaluation of the antipsychotic potential of the mGlu2-positive allosteric modulator JNJ-40411813". Pharmacology Research & Perspectives 3 (2): e00097. March 2015. doi:10.1002/prp2.97. PMID 25692027.

[WalkerConn2015-4] 4.0 ^4.1 "Group I and group II metabotropic glutamate receptor allosteric modulators as novel potential antipsychotics". Current Opinion in Pharmacology 20: 40–5. February 2015. doi:10.1016/j.coph.2014.11.003. PMID 25462291.

[DunlopBrandon2015-5] "Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations?". Journal of Psychopharmacology 29 (2): 230–8. February 2015. doi:10.1177/0269881114565806. PMID 25586401.

[Addex2014-6] Addex Therapeutics (7 February 2014). "Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms". http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder/.

[1]

[2]

[3]

[4]

[5]

[6]

ADX-71149

Topic: Chemistry

See also

References

External links

Clinical data

ATC code	None
Identifiers
IUPAC name 1-Butyl-3-chloro-4-(4-phenylpiperidin-1-yl)-1,2-dihydropyridin-2-one
CAS Number	1127498-03-6
PubChem CID	25195461
IUPHAR/BPS	8946
ChemSpider	28424210
UNII	612BYT76F3
ChEMBL	ChEMBL3337527
Chemical and physical data
Formula	C₂₀H₂₅ClN₂O
Molar mass	344.88 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CCCCN1C=CC(=C(C1=O)Cl)N2CCC(CC2)C3=CC=CC=C3
InChI InChI=1S/C20H25ClN2O/c1-2-3-12-23-15-11-18(19(21)20(23)24)22-13-9-17(10-14-22)16-7-5-4-6-8-16/h4-8,11,15,17H,2-3,9-10,12-14H2,1H3 Key:HYOGJHCDLQSAHX-UHFFFAOYSA-N